CureVac and partner GSK are, meanwhile, also developing an mRNA-based flu vaccine, but are a little further back in development, as their shot is in phase 1 testing. Influenza causes 140,000 to ...

A Massachusetts biopharma giant is at the center of preparations already underway if bird flu mutates and begins to find ...

A pandemic is not inevitable, scientists say. But the outbreak has passed worrisome milestones in recent weeks, including ...

In 2023, Moderna initiated a study on a “pandemic influenza vaccine” to protect ... Moderna plans to advance research on the mRNA vaccine into a phase 3 trial after receiving positive results ...

Elsewhere in the influenza market, FluGen has published the results of a Phase I trial showing that its intranasal flu vaccine, M2SR, increases in efficacy when used in when used in combination ...

Last year, Moderna completed a Phase I/II clinical trial of an investigational influenza vaccine called mRNA-1018, which was tested against H5 and H7 bird flu subtypes. The company said in a Jan. 17 ...

According to leading data and analytics company GlobalData, there are 12 vaccines in active clinical development (Phases I-III) indicated for pandemic influenza/influenza A(H5N1). Five of these ...

Traws Pharma has completed the Phase I clinical trials of tivoxavir marboxil, a single-dose drug for treating or preventing ...

for active immunization to prevent pandemic influenza disease caused by H5N1 virus. The randomized placebo-controlled Phase 1 trial (NCT06602531) is being conducted at multiple sites in the U.S ...

The US Department of HHS is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu.

The Department of Health and Human Services (HHS) will award roughly $590 million to Moderna to accelerate the development of mRNA-based pandemic influenza vaccines, including vaccines for avian flu ...